Puma Biotechnology, Inc. (PBYI) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zevra Therapeutics, Inc.

Applied Therapeutics, Inc.

Alimera Sciences, Inc.

Karyopharm Therapeutics, Inc.

OptiNose, Inc.

Puma Biotechnology, Inc.

Atara Biotherapeutics, Inc.

Adverum Biotechnologies, Inc.

PDS Biotechnology Corp.

Actinium Pharmaceuticals, Inc.

ESSA Pharma, Inc.

Why is Puma Biotechnology, Inc. ?

With a fall in Net Sales of -40.61%, the company declared Very Negative results in Mar 26

ROCE(HY) Lowest at 21.62%
INVENTORY TURNOVER RATIO(HY) Lowest at 6.65 times
NET SALES(Q) Lowest at USD 44.81 MM

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Puma Biotechnology, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Puma Biotechnology, Inc.

110.79%

1.52

70.56%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.28%

EBIT Growth (5y)

26.36%

EBIT to Interest (avg)

1.37

Debt to EBITDA (avg)

0.17

Net Debt to Equity (avg)

-0.32

Sales to Capital Employed (avg)

1.50

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

111.58%

ROE (avg)

32.87%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.37

EV to EBIT

6.26

EV to EBITDA

4.84

EV to Capital Employed

4.28

EV to Sales

1.02

PEG Ratio

9.94

Dividend Yield

ROCE (Latest)

68.37%

ROE (Latest)

23.87%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 53.61 MM

DEBT-EQUITY RATIO (HY)

Lowest at -68.28 %

RAW MATERIAL COST(Y)

Fallen by 0.42% (YoY

-26What is not working for the Company

ROCE(HY)

Lowest at 21.62%

INVENTORY TURNOVER RATIO(HY)

Lowest at 6.65 times

NET SALES(Q)

Lowest at USD 44.81 MM

OPERATING PROFIT(Q)

Lowest at USD -1.33 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -2.96 %

PRE-TAX PROFIT(Q)

Lowest at USD -3.43 MM

NET PROFIT(Q)

Lowest at USD -3.75 MM

EPS(Q)

Lowest at USD -0.07

Here's what is working for Puma Biotechnology, Inc.

Debt-Equity Ratio

Lowest at -68.28 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Operating Cash Flow

Highest at USD 53.61 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Raw Material Cost

Fallen by 0.42% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Puma Biotechnology, Inc.

Net Sales

At USD 44.81 MM has Fallen at -21.51%

over average net sales of the previous four periods of USD 57.09 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -3.43 MM has Fallen at -138.31%

over average net sales of the previous four periods of USD 8.95 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -3.75 MM has Fallen at -148.25%

over average net sales of the previous four periods of USD 7.78 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Sales

Lowest at USD 44.81 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Operating Profit

Lowest at USD -1.33 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at -2.96 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD -3.43 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -3.75 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.07

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Inventory Turnover Ratio

Lowest at 6.65 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio